Adult Dosing

Prevention of nausea/vomiting associated with chemotherapy

• 100 mg PO within 1 hr prior to chemotherapy

Prevention of post-operative nausea/vomiting

• 100 mg PO within 2 hrs prior to surgery

Pediatric Dosing

Prevention of nausea/vomiting associated with chemotherapy

• 2-16 yrs: 1.8 mg/kg PO within 1 hr prior to chemotherapy
• Max: 100 mg/dose

Prevention of post-operative nausea/vomiting

• 2-16 yrs: 1.2 mg/kg PO within 2 hrs prior to surgery
• Max: 100 mg/dose

[Outline]

• Adult Dosing
• Pediatric Dosing

• Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repetitive courses of therapy
• Prevention of postoperative nausea and vomiting

• Hypersensitivity to any of the ingredients of the product
• Congenital QT prolongation
• Hypokalemia
• Hypomagnesemia

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments
• Hemodialysis: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

• Therapy is associated with changes in ECG interval (PR, QTc, JT prolongation and QRS widening). Cardiovascular consequences, including heart block or cardiac arrhythmias have occurred on prolongation of intervals
• Possibility of cardiac conduction abnormality exists
• Occassions of death have occurred in association with therapy
• Rare occassions of sustained supraventricular and ventricular arrhythmias, cardiac arrest leading to death, and myocardial infarction have occurred in children and adolescents
• Possibility of development for cross hypersensitivity reactions in patients receiving other selective 5HT3 receptor antagonist exists
• Monitor K, Mg at baseline, then if essential after administration of this drug; Determine ECG and blood pressure if bradycardia, CHF

Cautions: Use cautiously in

• Renal impairment
• Cardiac conduction defects
• QT prolongation
• Congenital QT syndrome
• QT prolonging agent use
• Electrolyte disturbances
• Hypokalemia
• Hypomagnesemia
• Concomitant administration of diuretics
• Cumulative high-dose anthracycline therapy
• Concomitant administration of antiarrhythmic drugs or other drugs leading to QT prolongation
• Pediatrics having risk for developing prolongation of cardiac conduction intervals particularly QTc

Pregnancy Category:B

Breastfeeding: Safety unknown; manufacturer advises caution.

• CV: QT prolongation, PR prolongation, arrhythmias, hypotension, bradycardia, tachycardia, hypertension
• CNS: Headache dizziness
• GI: Diarrhea, dyspepsia
• GU: Oliguria
• DERM: Pruritus
• MISC: Fatigue, fever, chills

• 5-HT (3) receptor antagonist; blocks effects of serotonin at receptor sites located in vagal nerve terminals and in the CTZ in the CNS
• Well absorbed
• Metabolized by liver to active metabolite hydrodolasetron; CYP450: 2D6, 3A4 substrate
• Renally excreted: 70% (53% hydrodolasetron as unchanged), feces: 30%
• Half-life:
• Dolasetron: <10 mins
• Hydrodolasetron: 8.1 hrs

US Trade Name(s)

• Anzemet

US Availability

Anzemet

• TABS: 50, 100 mg

Canadian Trade Name(s)

• Anzemet

Canadian Availability

Anzemet

• TABS: 50, 100 mg

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• Anzemet

Australian Availability

Anzemet

• TABS: 50, 200 mg

[Outline]

Gastrointestinal

Antiemetics

5HT3 Receptor Antagonists

Hematology/Oncology

Antiemetics

5HT3 Receptor Antagonists

Pricing data from www.DrugStore.com in U.S.A.

• Anzemet 100 MG TABS [Bottle] (SANOFI-AVENTIS U.S.)
  5 mg = $355.96
  10 mg = $699.96

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

Drug Name: Anzemet 100 MG Oral Tablet

Pill Image:

[
See full size image]

Ingredient(s): Dolasetron

Imprint: 100;ANZEMET

Color(s): Pink

Shape: Oval

Size (mm): 13.00

Score: 1

Inactive Ingredient(s): carnauba wax / croscarmellose sodium / hypromellose / lactose / magnesium stearate / polyethylene glycol / polysorbate 80 / pregelatinized starch / synthetic red iron oxide / titanium dioxide / white wax / lecithin / pharmaceutical glaze / propylene glycol / synthetic black iron oxide

Drug Label Author:
sanofi-aventis. U.S. LLC

DEA Schedule:
Non-Scheduled

Drug Name: Anzemet 50 MG Oral Tablet

Pill Image:

[
See full size image]

Ingredient(s): Dolasetron

Imprint: A;50

Color(s): Pink

Shape: Round

Size (mm): 7.00

Score: 1

Inactive Ingredient(s): carnauba wax / croscarmellose sodium / hypromellose / lactose / magnesium stearate / polyethylene glycol / polysorbate 80 / pregelatinized starch / synthetic red iron oxide / titanium dioxide / white wax / lecithin / pharmaceutical glaze / propylene glycol / synthetic black iron oxide

Drug Label Author:
sanofi-aventis. U.S. LLC

DEA Schedule:
Non-Scheduled